We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

228 hedge funds and large institutions have $2.31B invested in Celldex Therapeutics in 2026 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 67 increasing their positions, 58 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

329% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 14

50% more funds holding in top 10

Funds holding in top 10: 6 → 9 (+3)

23% more funds holding

Funds holding: 185 → 228 (+43)

16% more capital invested

Capital invested by funds: $2B → $2.31B (+$314M)

16% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 58

1.19% less ownership

Funds ownership: 110.21% → 109.01% (-1.2%)

38% less call options, than puts

Call options by funds: $3.79M | Put options by funds: $6.1M

Holders
228
Holders Change
+43
Holders Change %
+23.24%
% of All Funds
2.81%
Holding in Top 10
9
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+50%
% of All Funds
0.11%
New
60
Increased
67
Reduced
58
Closed
14
Calls
$3.79M
Puts
$6.1M
Net Calls
-$2.31M
Net Calls Change
-$3.85M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$40.1M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.1M
3
IC
Ikarian Capital
Texas
+$12.6M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$11.1M
5
EP
Eversept Partners
New York
+$9.63M

Top Sellers

1
BG
Bellevue Group
Switzerland
-$65.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$31.6M
3
PCH
Polar Capital Holdings
United Kingdom
-$27.4M
4
DTC
Deep Track Capital
Connecticut
-$16.8M
5
EAM
Eventide Asset Management
Massachusetts
-$16.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
RIL
201
Rothschild Investment LLC
Illinois
$3.77K +$736 +27 +29%
LFG
202
Larson Financial Group
Missouri
$3.58K -$1.15K -42 -27%
HNB
203
Huntington National Bank
Ohio
$3.46K – – –
AAP
204
Arax Advisory Partners
Colorado
$2.82K +$55 +2 +2%
AF
205
Allworth Financial
California
$2.73K +$436 +16 +23%
JWM
206
JPL Wealth Management
Colorado
$2.38K +$2.04K +75 New
Jones Financial Companies
207
Jones Financial Companies
Missouri
$2.12K +$300 +11 +19%
TFGT
208
TS Financial Group (TSFG)
Illinois
$2K – – –
PFBT
209
Parkside Financial Bank & Trust
Missouri
$1.62K – – –
TPWA
210
Twin Peaks Wealth Advisors
California
$1.46K +$1.25K +46 New
Fifth Third Bancorp
211
Fifth Third Bancorp
Ohio
$969 +$845 +31 New
PWMG
212
Private Wealth Management Group
New Jersey
$889 – – –
GIA
213
GHP Investment Advisors
Colorado
$793 – – –
BWA
214
Basecamp Wealth Advisors
Washington
$761 – – –
AssetMark Inc
215
AssetMark Inc
California
$666 +$572 +21 New
SS
216
SBI Securities
Japan
$571 -$27 -1 -5%
MPWT
217
MassMutual Private Wealth & Trust
Connecticut
$571 +$491 +18 New
FFO
218
Fortitude Family Office
Arizona
$508 +$436 +16 New
TWD
219
True Wealth Design
Ohio
$476 +$109 +4 +36%
MCM
220
MAI Capital Management
Ohio
$254 +$218 +8 New
SA
221
Scarborough Advisors
Maryland
$190 – – –
IA
222
IFP Advisors
Florida
$159 – – –
EP
223
Essential Partners
California
$95 +$82 +3 New
II
224
Inspire Investing
Idaho
$32 – – –
MIM
225
MTM Investment Management
South Carolina
$32 – – –
6 7 8
9
10

CLDX Hedge Fund Activity: Q1 2026 in Review

228 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2026, worth a combined $2.31B — up 16% from $2B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new CLDX positions and 14 closed out — a net gain of 46 holders — while 67 added to existing stakes and 58 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $40.1M. The largest seller was Bellevue Group, cutting an estimated $65.9M.

  • 228 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2026, up from 185 in Q4 2025.
  • Funds reported $2.31B of Celldex Therapeutics stock for Q1 2026, up 16% quarter-over-quarter.
  • 60 funds opened new Celldex Therapeutics positions in Q1 2026 and 14 closed out, a net change of +46 holders.
  • The largest Celldex Therapeutics buyer in Q1 2026 was Point72 Asset Management, an estimated $40.1M added.
  • The largest Celldex Therapeutics seller in Q1 2026 was Bellevue Group, an estimated $65.9M sold.

Based on aggregated 13F filings for Q1 2026.